The NYSE pre-market update on September 9, 2026, featured key developments including defense company Covenant emerging from stealth with a new factory and heavy-payload weapon system, backed by over $250 million in funding. Moonwalk Bio announced progress in RNAi treatments aimed at reducing body fat while preserving muscle, with clinical trials expected in late 2027. Additionally, Brent Crude oil prices topped $100 a barrel amid Middle East tensions, influencing market outlook ahead of upcoming inflation data. These updates provide insights into defense innovation, biotech advancements, and commodity price shifts impacting investors.
This week saw significant declines in AI infrastructure stocks, with neocloud companies like CoreWeave and Nebius dropping over 30% in October. Credit default swap spreads for major tech firms Meta, Nvidia, and Oracle hit record highs, signaling incr...
Oracle's stock price has dropped nearly 50% from around $250 in early June to about $125, yet Wall Street analysts remain optimistic. Goldman Sachs recently maintained a 'Buy' rating, though it lowered the 12-month price target from $240 to $206 due ...
Oracle's stock has dropped 32% in 2026 despite strong cloud business growth, including 62% cloud revenue increase and $664 billion in future contracts. Analysts see a 54% upside potential with a price target of $201.27, driven by high GPU utilization...
Oracle announced it will hold its Investor Day Meeting on October 28, 2026, during Oracle AI World. The event will be streamed live, providing investors insights into Oracle's integrated cloud applications and autonomous infrastructure. This meeting ...
Oracle announced a $1 billion investment over four years to enhance its partner ecosystem's ability to develop AI-powered solutions and services. This funding expands benefits and incentives in training, technical support, cloud migration, and go-to-...
